Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent transaction reported to the Securities and Exchange Commission, Nancy J. Gagliano, a director at OraSure Technologies Inc. (NASDAQ:OSUR), acquired 12,750 shares of the company’s common stock. According to InvestingPro data, this insider purchase comes as the stock has declined about 13% in the past week, suggesting management’s confidence in the company’s prospects. The purchase was made on February 27, 2025, at a price of $3.08 per share, totaling $39,270. Following this transaction, Gagliano now holds a total of 91,524 shares in the company. This acquisition reflects Gagliano’s continued investment in OraSure Technologies, a firm known for its medical instruments and apparatus. InvestingPro analysis indicates the company is currently undervalued, with a strong current ratio of 9.95 and analysts projecting profitability this year. Get access to 8 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, OraSure Technologies reported its fourth-quarter 2024 earnings, revealing a revenue of $37.4 million, which slightly exceeded the consensus estimate of $36.8 million. The company’s core business revenue grew by 10% year-over-year, contributing $36.5 million to the total, while COVID-19 related revenue accounted for approximately $1 million. Despite the revenue beat, OraSure’s gross margin fell short of expectations, reported at 40.1% against the anticipated 43.4%. This shortfall was attributed to a decrease in COVID-19 testing revenue and changes in international sales mix. Looking ahead, OraSure has provided guidance for the first quarter of 2025, with expected revenue ranging from $27.5 million to $31.5 million. Citi analyst Patrick Donnelly maintained a Buy rating on OraSure’s shares but reduced the price target from $9 to $6, reflecting concerns over future revenue uncertainties. The company has also secured FDA approval for its OraQuick HIV Self Test and completed the acquisition of Sherlock Biosciences to expand its molecular diagnostics platform. These developments indicate ongoing strategic efforts to drive future growth despite challenges in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.